Orforglipron
Also known as: LY3502970, OWL833
An oral non-peptide GLP-1 receptor agonist. Could provide injection-free alternative to semaglutide and tirzepatide.
Mechanism of Action
Orforglipron is a small molecule that activates GLP-1 receptors similarly to peptide GLP-1 agonists. Being a non-peptide allows oral bioavailability without the special formulation needed for oral semaglutide.
Research Summary
Phase 2 trials showed up to 14.7% weight loss at 36 weeks with daily dosing. Comparable efficacy to injectable GLP-1s. Phase 3 trials ongoing for diabetes and obesity.
Research Protocols
Note: Doses from clinical trials
Common Doses
- •12-45mg once daily
- •Various doses in trials
Duration
Long-term use expected
Administration
Oral tablet daily
Side Effects & Considerations
- •GI effects (nausea, vomiting)
- •Similar to injectable GLP-1 class
- •Phase 3 will provide more data
References
Want updates on Orforglipron research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.
Educational Information Only
This information is provided for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare providers before making any decisions about peptides or other substances. The protocols listed reflect doses observed in research studies, not recommendations.